The critical role of NF-kB signaling in MM pathogenesis is supported by the clinical success of proteasome inhibitors in patients with relapsed, refractory myeloma [10] that partly act through NF-kB inhibition [11]. The gene discussed is NFKB1; the disease is Miyoshi myopathy.